WARNING: TOCOYSIS Oral terbutaline sulfate has not been approved for and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. During pregnancy, serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women.
In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Contraindications-Tocolysis]
Use: Labeled indications
- INDICATIONS AND USAGE Terbutaline Sulfate Tablets USP are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with…
Full indications and usage US FDA label
INDICATIONS AND USAGE Terbutaline Sulfate Tablets USP are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
Contraindications
CONTRAINDICATIONS 1. Tocolysis Oral terbutaline sulfate is contraindicated for the treatment of acute or maintenance tocolysis [see Boxed Warning: Tocolysis]. 2. Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Adults The usual oral dose of terbutaline sulfate tablets for adults is 5 mg administered at approximately six-hour intervals, three times daily, during the hours the patient is usually awake. If side effects are particularly disturbing, the dose may be reduced to 2.5 mg three times daily, and still provide a clinically significant improvement in pulmonary function.
The total dose within 24 hours should not exceed 15 mg. Children Terbutaline sulfate tablets are not recommended for use in children below the age of 12 years. A dosage of 2.5 mg three times daily is recommended for children 12 to 15 years of age. The total dose within 24 hours should not exceed 7.5 mg. If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is often a sign of seriously worsening asthma that would require reassessment of therapy.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Terbutaline sulfate tablets are not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness [see Dosage and Administration].
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of terbutaline sulfate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Syrup: 1.5 mg/5 mL
- Tablet: 2 mg, 2.5 mg
- ) solution for nebulizing: 2.5 mg/mL (5 mg/2 mL
- Solution for injection: 500 mcg/mL
- Syrup tablet: 1.5 mg/5 mL
Registered products in the Philippines
12 products registered with the Food and Drug Administration (FDA) Philippines list Terbutaline as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products12
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BricalinTerbutaline Sulfate | 500 mcg/mL Solution for Injection (IV/IM/SC)USP Type I Clear Colorless Glass Ampoule x 1 mL (Box of 50's) | Rx | L.B.S. Laboratory Limited PartnershipThailand | Phil Pharmawealth, Inc. | DR-XY29330 | Jan 28, 2029 | |
BricanylTerbutaline Sulfate | 2.5 mg TabletAlu-PVC Blister Pack x 20's in monocarton of 100's (Box of 500's) | Rx | AstraZeneca Pharmaceutical Company Ltd.China | AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-XY39882 | Aug 11, 2031 | |
BricanylTerbutaline Sulfate | 2.5 mg/mL (5mg/2mL) Solution for NebulizingPolyethylene (PE) Plastic Ampoule in 2 mL (net content) x 5's wrapped in white aluminium pouch (Box of 20's) | Rx | Astrazeneca ABSweden | Importer: AstraZeneca Pharmaceuticals (Phils.), Inc. | DR-XY1680 | Apr 23, 2031 | |
BroncodamTerbutaline Sulfate | 1.5 mg/5 mL SyrupAmber Colored Glass Bottle x 60 mL (Box of 1's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Filadams Pharma, Inc. | DRP-2390-02 | May 25, 2031 | |
Bucanil (Reformulated)Terbutaline Sulfate | 1.5mg/5mL SyrupPET Bottle x 60mL Box of 1's | Rx | Y.S.P. INDUSTRIES (M) SDN. BHD.Malaysia | Yung Shin (Philippines), Inc. | DR-XY28979 | Aug 30, 2028 | |
LungexTerbutaline Sulfate | 2.5 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-6400 | Sep 16, 2030 | |
PulmoClearTerbutaline Sulfate | 1.5 mg / 5 mL Syrup60 mL Amber Colored Glass Bottle (Box of 1's) | Rx | Scheele Laboratories Phils. Inc.Philippines | — | DRP-2390 | Mar 15, 2031 | |
PulmoxcelTerbutaline Sulfate | 1.5 mg / 5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY17310 | Oct 25, 2029 | |
PulmoxcelTerbutaline Sulfate | 2 mg TabletAluminum Foil strip x 10's (Box of 100's) | Rx | HIZON LABORATORIES, INC.Philippines | Trader: GX INTERNATIONAL, INC. | DR-XY15513-B | Jan 8, 2029 | |
TerbusaphTerbutaline sulfate | 1.5 mg/5 mL Syrup (Raspberry Flavor) TabletPET Round Amber Bottle Sealed with White ROPP Aluminum Cap x 60 mL and 120 mL (Box of 1's) | Rx | Azine Healthcare Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciencess Pvt. Ltd | DRP-14101 | Jun 21, 2028 | |
VentasmaTerbutaline Sulfate | 1.5 mg / 5 mL SyrupAmber Colored Glass Bottle x 60 mL (Box of 1's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Zeutica, Inc. | DRP-2390-01 | Mar 23, 2031 | |
VentrylTerbutaline (as Sulfate) | 1.5 mg/5 mL SyrupBoston Round Amber Glass Bottle x 60mL (Box of 1's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DR-XY24095 | Jan 29, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Deterioration of Asthma Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. Cardiovascular Effects Terbutaline sulfate, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms.
Although such effects are uncommon after administration of terbutaline sulfate tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.
The clinical significance of these findings is unknown. Therefore, terbutaline sulfate tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Seizures There have been rare reports of seizures in patients receiving terbutaline; seizures did not recur in these patients after the drug was discontinued.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. However, this does not preclude the use of an aerosol bronchodilator of the adrenergic-stimulant type for the relief of an acute bronchospasm in patients receiving chronic oral therapy with terbutaline sulfate tablets.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Adverse reactions observed with terbutaline sulfate are similar to those commonly seen with other sympathomimetic amines. All of these reactions are generally transient in nature and usually do not require treatment. The frequency of these side effects appears to diminish with continued therapy. The following table lists the adverse reactions seen in 199 patients treated with terbutaline sulfate tablets during six double-blind crossover studies and four double-blind parallel studies (short- and long-term) performed in the United States.
Percent Incidence of Adverse Reactions (Total Daily Dosage Range 5 to 15 mg) Terbutaline N=199 Reaction % Nervous System Nervousness 35.0 Tremor 15.0 Somnolence 5.5 Dizziness 3.5 Anxiety 1.0 Insomnia 1.5 Cardiovascular Palpitations 5.0 Tachycardia 3.5 Extrasystoles ventricular 1.5 Vasodilations 1.0 Digestive Nausea 3.0 Dry mouth 1.5 Body as a Whole Headache 7.5 Asthenia 2.0 Skin and Appendages Sweating 1.0 The following adverse reactions each occurred in fewer than 1% of patients: hallucinations, rash, paresthesia, hypertonia, (muscle cramps), vomiting. There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis.
To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-800-308-6755 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Adverse reaction frequency tables (US label) US FDA label
| Percent Incidence of Adverse Reactions (Total Daily Dosage Range 5 to 15 mg) Terbutaline N=199 | |
| Reaction | % |
| Nervous System | |
| Nervousness | 35.0 |
| Tremor | 15.0 |
| Somnolence | 5.5 |
| Dizziness | 3.5 |
| Anxiety | 1.0 |
| Insomnia | 1.5 |
| Cardiovascular | |
| Palpitations | 5.0 |
| Tachycardia | 3.5 |
| Extrasystoles ventricular | 1.5 |
| Vasodilations | 1.0 |
| Digestive | |
| Nausea | 3.0 |
| Dry mouth | 1.5 |
| Body as a Whole | |
| Headache | 7.5 |
| Asthenia | 2.0 |
| Skin and Appendages | |
| Sweating | 1.0 |
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether this drug is excreted in human milk. Therefore, terbutaline sulfate tablets should be used during nursing only if the potential benefit justifies the possible risk to the newborn.
Pharmacokinetics
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours.
The terminal half-life was determined in 9 of the 17 subjects and had a mean (SD) of 5.7 (2.0) hours.
About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug.
The sulfate conjugate is a major metabolite of terbutaline, and urinary excretion is the primary route of elimination.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics Oral administration of 5 mg terbutaline sulfate tablets or 5 mg terbutaline sulfate in solution in 17 healthy, adult, male subjects, resulted in mean (SD) peak plasma terbutaline concentration of 8.3 (3.9) and 8.6 (3.6) ng/mL, which were observed at median (range) times of 2 (1 to 3) and 1.5 (0.5 to 3.0) hours after dosing. The mean (SD) AUC (0 to 48) values were 54.6 (26.8) and 53.1 (23.5) hr•ng/mL, and corresponded to a bioavailability of 103% for the tablet relative to the solution.
After oral administration of terbutaline, 51 to 62 mcg/kg of body weight, to 3 healthy male subjects, peak serum levels of 3.1 to 6.2 ng/mL were observed 1 to 3 hours later. In the same study, after 3 days only 30% to 50% of the dose was recovered from urine and the remainder from the feces, which may indicate poor absorption.
After an oral dose to asthmatic patients, the elimination half-life of terbutaline was approximately 3.4 hours. In comparison to oral dosing, subcutaneous administration of 0.5 mg of terbutaline sulfate to 17 healthy, adult, male subjects resulted in a mean (SD) peak plasma terbutaline concentration of 9.6 (3.6) ng/mL, which was observed at a median (range) time of 0.5 (0.08 to 1.0) hours after dosing.
The mean (SD) AUC (0 to 48) and total body clearance values were 29.4 (14.2) hr•ng/mL, and 311 (112) mL/min, respectively. The terminal half-life was determined in 9 of the 17 subjects and had a mean (SD) of 5.7 (2.0) hours. About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug.
The sulfate conjugate is a major metabolite of terbutaline, and urinary excretion is the primary route of elimination. There are no reports of any clinical pharmacokinetic studies investigating dose proportionality, effect of food, or special population studies with terbutaline.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Terbutaline 500 mcg/mL, 1 mL Ampule | ₱39.98–₱98.00Reference ₱39.98 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Terbutaline (as sulfate) |
| PNF listing | Oral: 5 mg tablet |
| PNF listing | Oral: 1.5 mg/5 mL syrup, 60 mL |
| PNF listing | Inj.: 500 micrograms/mL, 1 mL ampul (IM, IV, SC) |
| PNF listing | Resp. Soln.: (for nebulization) 2.5 mg/mL, 2 mL unit dose |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Terbutaline Sulfate · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 2, November 15, 2019]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d810a15b-3e10-4f6c-a36e-8ddecbaba9c3
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .